- Home
- MREO vs GAU Comparison
MREO vs GAU Comparison
Compare MREO & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- GAU
- Stock Information
- Founded
- MREO 2015
- GAU 1999
- Country
- MREO United Kingdom
- GAU Canada
- Employees
- MREO N/A
- GAU N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- GAU
- Sector
- MREO Health Care
- GAU
- Exchange
- MREO Nasdaq
- GAU Nasdaq
- Market Cap
- MREO 424.5M
- GAU 342.0M
- IPO Year
- MREO N/A
- GAU N/A
- Fundamental
- Price
- MREO $2.85
- GAU $1.36
- Analyst Decision
- MREO Strong Buy
- GAU Strong Buy
- Analyst Count
- MREO 7
- GAU 1
- Target Price
- MREO $7.71
- GAU $2.80
- AVG Volume (30 Days)
- MREO 1.2M
- GAU 1.6M
- Earning Date
- MREO 08-12-2025
- GAU 08-07-2025
- Dividend Yield
- MREO N/A
- GAU N/A
- EPS Growth
- MREO N/A
- GAU N/A
- EPS
- MREO N/A
- GAU N/A
- Revenue
- MREO N/A
- GAU $276,234,000.00
- Revenue This Year
- MREO N/A
- GAU $70.62
- Revenue Next Year
- MREO $54.07
- GAU $40.51
- P/E Ratio
- MREO N/A
- GAU N/A
- Revenue Growth
- MREO N/A
- GAU 771.54
- 52 Week Low
- MREO $1.58
- GAU $1.00
- 52 Week High
- MREO $5.02
- GAU $2.00
- Technical
- Relative Strength Index (RSI)
- MREO 64.74
- GAU 46.20
- Support Level
- MREO $2.61
- GAU $1.36
- Resistance Level
- MREO $2.85
- GAU $1.56
- Average True Range (ATR)
- MREO 0.17
- GAU 0.09
- MACD
- MREO 0.03
- GAU -0.01
- Stochastic Oscillator
- MREO 88.83
- GAU 7.50
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.